In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Earlier at ADA, Lilly reported phase 2 results with its once-daily oral GLP-1 agonist orforglipron, which achieved a weight reduction of almost 15% at 24 weeks, potentially giving Lilly the option ...

Medscape Medical News, June 25, 2024 ADA 2024 GLP-1 Kidney Benefits Seen With or Without SGLT2 Inhibitors Larger studies are needed because of the low numbers of patients on SGLT2 inhibitors in ...

and at ADA the drugmaker also reported mid-stage results with its oral candidate orforglipron, a non-peptide GLP-1 agonist. The study – published in the New England Journal of Medicine ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm.

The Biden administration is set to propose legislation allowing Medicare and Medicaid to cover the cost of GLP-1 obesity meds such as Wegovy and Zepbound The Trump administration will have to ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered. Advertisement Under the Medicaid system ...

Taking a GLP-1 Medication? Here's Tips to Holiday Eating By Robin Foster HealthDay Reporter SATURDAY, Nov. 23, 2024 (HealthDay News) -- So, you have managed to shed 30 pounds with the help of one ...